Media Thread, page-4102

Biotech Tidy up your labs, biotech. Pfizer is coming with 'significant firepower' and cash to burn

The following is an excerpt from the article above:

Pfizer plans to be “thoughtful and disciplined about resource allocation,” according to Aamir Malik, executive VP and chief business innovation officer. But the company has set two priorities for future acquisitions: compelling later stage assets that can provide revenue in the back half of the decade and potential medical breakthroughs in earlier stage development.

Reading the bold italic part of the excerpt, IMU fits that description perfectly! Some of IMU's B cell candidates like Her-Vaxx and PD1-Vaxx should provide revenue in the back half of the decade. And regarding potential medical breakthroughs in earlier stage development, well hello...CF33, Checkvacc and Vaxinia!

And then there is this excerpt:

And don’t rule out a blockbuster deal just yet: Malik said that if a larger opportunity comes up, Pfizer is willing to pounce. Several large transactions, at $50 billion or more, are likely to occur next year, PwC predicted last week.

With their Covid windfall, Pfizer certainly has the potential to make that kind of move on IMU. And it can potentially happen next year as predicted by PwC

Good luck!